Cargando…
Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
OBJECTIVE: To develop a multimarker prognostic score for infective endocarditis (IE). DESIGN: Retrospective case–control. SETTING: Secondary care. Single centre. PARTICIPANTS: 125 patients with definite IE. PRIMARY OUTCOME MEASURES: 90-day and 5-year mortality. RESULTS: Mean age was 62.7±17 years. T...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400063/ https://www.ncbi.nlm.nih.gov/pubmed/22798251 http://dx.doi.org/10.1136/bmjopen-2012-000856 |
_version_ | 1782238454824828928 |
---|---|
author | Bjurman, Christian Snygg-Martin, Ulrika Olaison, Lars Fu, Michael L X Hammarsten, Ola |
author_facet | Bjurman, Christian Snygg-Martin, Ulrika Olaison, Lars Fu, Michael L X Hammarsten, Ola |
author_sort | Bjurman, Christian |
collection | PubMed |
description | OBJECTIVE: To develop a multimarker prognostic score for infective endocarditis (IE). DESIGN: Retrospective case–control. SETTING: Secondary care. Single centre. PARTICIPANTS: 125 patients with definite IE. PRIMARY OUTCOME MEASURES: 90-day and 5-year mortality. RESULTS: Mean age was 62.7±17 years. The 90-day and 5-year mortality was 10.4% and 33.6%, respectively. CysC levels at admission and over 20% increases in CysC levels during 2 weeks of treatment were prognostic for 90-day and 5-year mortality independent of creatinine estimated glomerular filtration rate. In multivariate analyses, CysC (OR 5.42, 95% CI 1.90 to 15.5, p=0.002) and age (OR 1.06, 95% CI 1.02 to 1.10, p=0.002) remained prognostic for 5-year mortality. NT-proBNP, TnT, C reactive protein and interleukin 6 were also linked to prognosis. A composite risk scoring system using levels of CysC, NT-proBNP, age and presence of mitral valve insufficiency was able to separate a high-risk and a low-risk group. CONCLUSIONS: CysC levels at admission and increase in CysC after 2 weeks of treatment were independent prognostic markers for both 90-day and 5-year mortality in patients with IE. A multimarker composite risk scoring system including CysC identified a high-risk group. |
format | Online Article Text |
id | pubmed-3400063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34000632012-07-23 Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study Bjurman, Christian Snygg-Martin, Ulrika Olaison, Lars Fu, Michael L X Hammarsten, Ola BMJ Open Cardiovascular Medicine OBJECTIVE: To develop a multimarker prognostic score for infective endocarditis (IE). DESIGN: Retrospective case–control. SETTING: Secondary care. Single centre. PARTICIPANTS: 125 patients with definite IE. PRIMARY OUTCOME MEASURES: 90-day and 5-year mortality. RESULTS: Mean age was 62.7±17 years. The 90-day and 5-year mortality was 10.4% and 33.6%, respectively. CysC levels at admission and over 20% increases in CysC levels during 2 weeks of treatment were prognostic for 90-day and 5-year mortality independent of creatinine estimated glomerular filtration rate. In multivariate analyses, CysC (OR 5.42, 95% CI 1.90 to 15.5, p=0.002) and age (OR 1.06, 95% CI 1.02 to 1.10, p=0.002) remained prognostic for 5-year mortality. NT-proBNP, TnT, C reactive protein and interleukin 6 were also linked to prognosis. A composite risk scoring system using levels of CysC, NT-proBNP, age and presence of mitral valve insufficiency was able to separate a high-risk and a low-risk group. CONCLUSIONS: CysC levels at admission and increase in CysC after 2 weeks of treatment were independent prognostic markers for both 90-day and 5-year mortality in patients with IE. A multimarker composite risk scoring system including CysC identified a high-risk group. BMJ Group 2012-07-12 /pmc/articles/PMC3400063/ /pubmed/22798251 http://dx.doi.org/10.1136/bmjopen-2012-000856 Text en © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Cardiovascular Medicine Bjurman, Christian Snygg-Martin, Ulrika Olaison, Lars Fu, Michael L X Hammarsten, Ola Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
title | Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
title_full | Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
title_fullStr | Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
title_full_unstemmed | Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
title_short | Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
title_sort | cystatin c in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400063/ https://www.ncbi.nlm.nih.gov/pubmed/22798251 http://dx.doi.org/10.1136/bmjopen-2012-000856 |
work_keys_str_mv | AT bjurmanchristian cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy AT snyggmartinulrika cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy AT olaisonlars cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy AT fumichaellx cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy AT hammarstenola cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy |